TSE:4503Pharmaceuticals
Astellas Pharma Q3 2026 Profit Rebound Challenges Bearish Earnings Narratives
Astellas Pharma (TSE:4503) has posted its Q3 2026 numbers, with revenue of ¥571,206 million (¥571.2 billion) and basic EPS of ¥56.04, alongside net income excluding extraordinary items of ¥100,379 million. The company has seen revenue move from ¥517,408 million and basic EPS of a loss of ¥54.57 in Q3 2025 to ¥571,206 million and EPS of ¥56.04 in Q3 2026. Trailing twelve month EPS sits at ¥180.31 on revenue of ¥2,060,614 million (¥2.1 trillion), giving investors a clearer view of how...